Biome Strain Development Program Success
● Biome has successfully completed the identification, commercial validation and initial characterisation of the probiotic strain Lactobacillus plantarum BMB18 ●… Read more
Biome Australia Business and International Market Update
● Following a successful test market launch in Canada, Biome moves to an official market launch in both health retail… Read more
Quarterly Activities & Appendix 4C September 2024
● Biome records $122k of EBITDA for Q1 (Adjusted for share based payments) ○ Third consecutive quarter of positive EBITDA… Read more
Biome reports record quarterly sales revenue for Q1 FY25
● Biome achieves record quarterly sales revenue of ~$4.25m (unaudited) ● Sales revenue increased ~$1.51m or 55% vs PCP Q1… Read more
Biome Australia Vision 27 Strategic Plan
Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific probiotic… Read more
Biome Commences Test Market in Canada
Biome Australia’s Founder and Managing Director, Blair Vega Norfolk, commented: “I am excited to announce this new partnership with Ecotrend… Read more
Biome Q1 FY25 Revenue Guidance
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to announce, after a strong start… Read more
Biome Investor Webinar Recording
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to provide access to the recording… Read more
Biome Investor Presentation
Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven condition-specific probiotic… Read more